Fig. 3: Relative risk of asymptomatic SARS-CoV-2 infection among vaccine recipients compared with the MenACWY control arm participants as a function of immune markers measured at PB28.
From: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
a, Anti-spike IgG measured at PB28 (91 cases, 1,155 noncases included in the analysis). b, Anti-RBD IgG measured at PB28 (91 cases, 1,155 noncases included in the analysis). c, Pseudovirus neutralization antibody titers at PB28 (86 cases, 828 noncases included in the analysis). d, Live-virus neutralization antibody titers at PB28 (62 cases, 412 noncases included in the analysis). Blue shaded areas represent the immune marker density distribution. Green lines show the relative risk of infection among vaccine recipients compared with the MenACWY control arm participants. The green lines are the median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are bootstrapped 95% CIs.
